Summary
Eli Lilly and Company reported solid revenue growth for the first six months of 2017, up 8% year-over-year to $11.05 billion. This growth was primarily driven by increased sales volume for key products like Trulicity and Taltz, along with contributions from recent acquisitions. However, net income for the six-month period saw a significant decline of 24% to $897.2 million. This decrease was largely due to a substantial $857.6 million acquired in-process research and development (IPR&D) charge related to the acquisition of CoLucid Pharmaceuticals, Inc. in March 2017, which was non-tax deductible. Despite the bottom-line dip, the company's financial health remains robust, with a healthy gross margin of 73.9% for the period. Lilly also continues to invest heavily in its pipeline, with numerous new molecular entities (NMEs) in late-stage clinical trials. However, investors should note the significant patent expirations on the horizon for key products like Cialis, Strattera, and Alimta, which are expected to materially impact future revenues and earnings. The company provided an updated full-year 2017 EPS guidance of $2.51 to $2.61 and revenue guidance of $22.0 billion to $22.5 billion.
Financial Highlights
53 data points| Revenue | $5.82B |
| Cost of Revenue | $1.55B |
| Gross Profit | $4.27B |
| R&D Expenses | $1.27B |
| SG&A Expenses | $1.73B |
| Operating Expenses | $3.00B |
| Interest Expense | $53.60M |
| Net Income | $1.01B |
| EPS (Basic) | $0.96 |
| EPS (Diluted) | $0.95 |
| Shares Outstanding (Basic) | 1.05B |
| Shares Outstanding (Diluted) | 1.06B |
Key Highlights
- 1Revenue increased by 8% to $11.05 billion for the first six months of 2017, driven by volume growth in key products like Trulicity and Taltz.
- 2Net income decreased by 24% to $897.2 million for the six months ended June 30, 2017, primarily due to an $857.6 million non-tax-deductible IPR&D charge from the CoLucid acquisition.
- 3The company made significant acquisitions, including Boehringer Ingelheim Vetmedica's vaccine portfolio for $882.1 million and CoLucid Pharmaceuticals for $831.8 million.
- 4Several important products are facing or will soon face patent expirations, including Strattera (already experienced in the U.S.), Cialis (expected in late 2017/late 2018 in the U.S. and Europe), and Alimta (facing patent challenges and generic entry).
- 5Eli Lilly has a strong late-stage pipeline with several NMEs in Phase III trials, including for Alzheimer's disease (Lanabecestat), migraine (Galcanezumab, Lasmiditan), and cancer (Abemaciclib, Lartruvo).
- 6The company reaffirmed its full-year 2017 revenue guidance of $22.0 billion to $22.5 billion and updated its full-year EPS guidance to $2.51 to $2.61.
- 7Total debt increased to $12.31 billion as of June 30, 2017, primarily due to new debt issuances to fund general corporate purposes.